



**International Journal of Biology, Pharmacy  
and Allied Sciences (IJBPAS)**

*'A Bridge Between Laboratory and Reader'*

[www.ijbpas.com](http://www.ijbpas.com)

---

**DEVELOPMENT AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM  
FOR CHRONOTHERAPEUTIC RELEASE OF METOPROLOL SUCCINATE USING  
PRESS-COATING METHOD**

**SARAVANAN G**

Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India

**Corresponding Author: G. Saravanan: E Mail: [drsaravanan.g@kahedu.edu.in](mailto:drsaravanan.g@kahedu.edu.in); Mobile**

**Number: 09959955325**

Received 12<sup>th</sup> April 2020; Revised 26<sup>th</sup> May 2020; Accepted 20<sup>th</sup> July 2020; Available online 1<sup>st</sup> Feb. 2021

<https://doi.org/10.31032/IJBPAS/2021/10.2.5341>

**ABSTRACT**

The current examination was done on the turn of events and assessment of Pulsatile Drug Delivery System for Chronotherapeutic Release of Metoprolol Succinate. The medication is having a biological half-life of 3-7 hours and is intended for the treatment of Hypertension. In the current examination time discharge tablets were set up by press-coating method. The plan included two stages. First was to prepare core tablets and second included the coating of core tablets with polymers. Super disintegrants like Cros-Povidone, Cros-Carmellose Sodium and Sodium Starch Glycolate were utilized for the formulating of core tablets and assessed for pre-compression and post compression boundaries as to recognize quick discharge character of medication for formulations. The best formulations among them having higher medication discharge with less span of time was selected and again concentrated further by coating with various polymers in various concentrations to hinder the medication discharge and to accomplish time-discharge pulsatile tablets. Natural polymers like Xanthum gum and Guar gum were utilized for coating as these are biodegradable and non-poisonous, which hydrate and swell on contact with fluid media. At long last, the created formulations were assessed for its physico chemical properties, dissolution rate, drug discharge mechanism and kinetics, stability and the best formulation was chosen. Along these lines from this investigation, Consistent lag time,

---

immediate release of the drug and the prerequisites for creating Pulsatile Drug Delivery System for chronotherapeutics was accomplished with the created formulation.

**Keywords: Pulsatile, Chronotherapeutics, Metoprolol Succinate, Super disintegrants, Natural polymers, lag time**

## INTRODUCTION

With the progression of innovation in the pharmaceutical field, Drug Delivery System have drawn an expanding enthusiasm in the course of the most recent couple of decades [1, 2]. In the field of current medication treatment, developing consideration has recently been centered around pulsatile conveyance of medications for which conventional controlled Drug Delivery System with a constant discharge are not perfect [3, 4]. Infection conditions where consistent medication levels are not liked yet need a beat of remedial focus in an intermittent way goes about as a push for the improvement of Pulsatile Drug Delivery System [5, 6]. In this way, the idea of chronotherapeutics has developed where in, research is dedicated to the design and assessment of drug delivery systems that discharge a Therapeutic agent at a rhythm that in a perfect world matches the organic necessities of a given sickness treatment. These frameworks have a particular system of conveying drug quickly and totally after a "lag time" for example a time of no medication discharge, portrayed by a

modified medication discharge [7]. These framework (pulsatile) are planned in a way that the medication is accessible at the site of activity at the opportune time in the perfect sum. These frameworks are valuable for drugs having high first pass effect; drugs regulated for infections that follow chronopharmacological conduct, drugs having explicit absorption site in GIT, focusing to colon and situations where night time dosing is required [8].

A few capacities, for example, Blood pressure (BP), pulse, stroke volume, cardiac output, blood stream of the cardiovascular system are dependent upon circadian rhythms. For example, capillary obstruction and vascular reactivity are higher toward the beginning of the day and diminishing later in the day. Platelet aggregability is expanded and fibrinolytic movement is diminished in the first part of the day, prompting a condition of relative hypercoagulability of the blood [9, 10]. It was hypothesized that adjustment of these circadian triggers by pharmacologic specialists may prompt the counteraction of unfavorable heart occasions.

BP is at its most minimal during the sleeping period and rises steeply during the early morning time. Most patients with basic hypertension have a comparable circadian beat of BP as do normotensive people, albeit hypertensive patients have an upward move in the profile [11, 12].

Metoprolol succinate is a  $\beta_1$  specific (Cardio selective) adrenoceptor blocking agent, for oral administration, accessible as extended release tablets [13]. It is utilized in treatment of a few sicknesses of the cardiovascular system, particularly hypertension. It works by lessening the measure of work the heart needs to do (decreases chest torment) and the measure of blood the heart siphons out (brings down hypertension) along these lines by treating angina and hypertension [14].

In the current examination press-coated time release tablets of Metoprolol succinate were created. The tablets, each comprising of a core and a coat, were readied utilizing direct compression technique. The core tablet was then coated with natural polymers, for example, Xanthun gum and Guar gum and blends of it in various extents. The impact of formulation composition on the hindrance layer involving the two polymers and excipients on the lag time of medication discharge was explored; for if the formulation is used in the night,

manifestations of Cardiovascular Diseases that are knowledgeable about early morning hours could be kept away from.

## METHODS

### Construction of Calibration Curve for Metoprolol succinate [15]

Precisely weighed 100mg of Metoprolol succinate was disintegrated in water in a 100ml volumetric cup and make up to 100ml with water.

The standard solution of Metoprolol succinate was again thusly diluted with water to get a progression of dilutes containing 2, 4, 6, 8, 10  $\mu\text{g/ml}$  concentrations of Metoprolol succinate per 1ml of solution. The absorbance of above dilutes was estimated in Lab India double beam UV Spectrophotometer at 275nm utilizing water as a blank. The concentrations of Metoprolol succinate and the comparing absorbance esteems are given in **Table 1**. The absorbance esteems are plotted against concentrations of Metoprolol succinate as appeared in **Figure 1**. The technique complied with Beer's law in the focus scope of 0-10 $\mu\text{g/ml}$ .

### Formulation of Metoprolol Succinate Tablets [16]

#### STAGE 1: Formulation of Rapid Release Core Tablets by Direct Compression

The inward core tablets were set up by utilizing direct compression technique according to formulation variable appeared in **Table 2**. Powder blends of Metoprolol succinate, Micro crystalline cellulose, Lactose spray dried, Cros-povidone, Cros-carmellose sodium and Sodium starch glycolate were dry mixed for 20 min. followed by expansion of magnesium stearate and Talc. The blends were then additionally mixed for 10 min. 150mg of resultant powder mix was physically compacted utilizing hydraulic press at a pressure of 1 ton, with a 9mm punch and die to get the core tablet.

#### **STAGE 2: Formulation of Mixed Blend for Barrier Layer**

The different formulation compositions containing Xanthan gum and Guar gum as appeared in table 6 were gauged, dry mixed at around 10 min. furthermore, utilized as press-coating material to get ready press-coated pulsatile tablets by direct compression technique.

#### **STAGE 3: Preparation of Press-Coated Tablets**

The streamlined core tablets were press-coated with 300mg of blended mix as given in Table 6, 150mg of barrier layer material was gauged and moved into a 13mm die then the core tablet was carefully positioned

physically at the inside. The staying 150mg of the barrier layer material was included into the die and compressed at a pressure of 5 tons for 3min. utilizing pressure driven press.

#### **Preformulation Studies [17, 18]**

##### **Bulk Density:**

In 100ml graduated cylinder the known measure of powder from every formulation is taken. Introductory volume was noted and the cylinder was fixed on density apparatus and the time handle was balanced for tapping and estimated the last volume subsequent to tapping. The Bulk Density of the powder was determined.

##### **Carr's Index and Hausner's Ratio:**

The level of compressibility of powder was dictated via Carr's compressibility Index. Hausner's ratio of powder was dictated by contrasting the tapped density with the bulk density utilizing formulae.

##### **Angle of Repose:**

The readied powders were estimated for its flow property by deciding the angle of repose by fixed funnel method. The angle of repose was determined.

##### **Infrared spectroscopy:**

Infrared spectroscopy was directed utilizing thermo Nicol nexus 670 spectrophotometer for examining the compatibility of the drug with the excipients. The sample (medicate alone or blend of medication and excipients)

is administered in a KBr and compacted into discs by applying a pressure. The acquired pellet was permitted in the light way and the spectrum was gotten. The spectrum was recorded in the wavelength region of 4000 to 400  $\text{cm}^{-1}$  and any adjustments in chemical composition of the medication in the wake of joining it with the excipients were examined with I.R Spectral Analysis.

### **Characterization of Core and Press Coated Tablets [19, 20, 21]**

#### **Post Compression Parameters:**

##### **General Appearance:**

The General Appearance of a tablet, its visual character (shading), clarity of any distinguishing marks for example over all 'elegance' is fundamental for buyer acknowledgment.

##### **Size and Shape:**

The tablet can be dimensionally portrayed, observed and controlled for its size and shape.

##### **Thickness:**

The thickness and width of the tablets are estimated by utilizing Vernier calipers. Three tablets from each clump were utilized and normal qualities were determined.

##### **Hardness:**

The tablet squashing quality, which is the power required to break the tablet by the pressure in the diametric way was estimated

in triplicate utilizing Pfizer tablet hardness analyzer.

##### **Friability:**

The Roche friability test apparatus was utilized to decide the friability of the tablets. 20 pre gauged tablets were put in the apparatus, which was exposed to 100 revolutions. At that point the tablets were rechecked. The percent friability was determined.

##### **Weight Variation:**

The formulated 20 tablets were weighed altogether and independently. From the aggregate weight, average weight was determined. Every tablet weight was then contrasted with average weight to verify whether it is inside admissible limits or not.

##### **Wetting Time:**

Five round tissue papers of 10 cm distance across are put in a petri dish. 10ml of water containing amaranth a water dissolvable dye is added to petri dish. A tablet is positioned on the surface of the tissue paper. The time required for water to arrive at upper surface of the tablet is noted as a wetting time.

##### **Water Absorption Ratio:**

A bit of tissue paper folded twice was set in a petri dish (10cm diameter) containing 6 ml of water. A tablet was put on the tissue paper and permitted to wet totally. The wetted

tablet was then rechecked. Water absorption ratio, R was resolved.

**Swelling Index:**

In this examination six tablets were set in the basket of dissolution apparatus by utilizing water as dissolution medium at  $37 \pm 0.50^\circ\text{C}$ . Tablets were pulled back at time span of 30 min., smeared with tissue paper to evacuate the abundance water and weighed on the analytical balance. The Swelling Index was determined.

**Disintegration Time:**

The test was done on 6 tablets utilizing the apparatus indicated in I.P.1996. Distilled water at  $37^\circ\text{C} \pm 2^\circ\text{C}$  was utilized as a disintegration media and the time in second taken for complete deterioration of the tablet with no palable mass staying in the device was estimated in seconds.

**Drug Content:**

Ten arbitrarily chosen tablets are weighed and average weight is determined. The tablets are powdered in a glass mortar. The weight proportional to tablet is weighed. The weighed sum is dissolved in solvent system in discrete volumetric flask utilizing magnetic stirrer, the volume is balanced with Sorenson's buffer pH 6.8 and the solution was sifted. An aliquot of these solution are

diluted with Sorenson's buffer pH6.8 in discrete volumetric flask in Lambert's – Beer's Range. The drug content in formulation is resolved spectrophotometrically without any problem.

**In Vitro Dissolution Study:**

Dissolution investigation of Metoprolol succinate core and press coated tablets was done utilizing USP type-II (paddles) dissolution apparatus utilizing 900 ml of distilled water kept up at  $37 \pm 0.50^\circ\text{C}$  at a speed of 100 rpm. At known normal stretches, 5 ml of sample of dissolution mediums were pulled back by methods for syringe fitted with pre-channel and examined for drug release by estimating the absorbance at 275 nm. The dissolution liquid was again acclimated to 900 ml by supplanting every 5 ml aliquot pulled back with 5 ml of water.

**Stability Studies:**

The stability studies were completed at room temperature ( $30^\circ\text{C} - 40^\circ\text{C}$ ) for 3 months by setting the tablets in a plastic zip sack. Toward the finish of this period tablets were examined for their Appearance and Drug content. The outcomes are appeared in **Table 2**. Likewise, the discharge pattern of the medication is analyzed before and after stability studies as appeared in **Figure 2**.

Table 1: Calibration Curve for Metoprolol succinate

| CONCENTRATION ( $\mu\text{g/ml}$ ) | ABSORBANCE ( $X \pm S.D$ ) |
|------------------------------------|----------------------------|
| 0                                  | 0                          |
| 2                                  | 0.011                      |
| 4                                  | 0.022                      |
| 6                                  | 0.033                      |
| 8                                  | 0.044                      |
| 10                                 | 0.053                      |




Figure 1: Calibration Curve for the Estimation of Metoprolol succinate

Table 2: Formulation of Metoprolol Succinate Core Tablets

| S.No. | INGREDIENTS                | F1 (mg) | F2 (mg) | F3 (mg) | F4 (mg) | F5 (mg) | F6 (mg) | F7 (mg) | F8 (mg) | F9 (mg) |
|-------|----------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| 1     | Metoprolol Succinate       | 100     | 100     | 100     | 100     | 100     | 100     | 100     | 100     | 100     |
| 2     | Microcrystalline Cellulose | 20.5    | 20.5    | 20.5    | 20.5    | 20.5    | 20.5    | 20.5    | 20.5    | 20.5    |
| 3     | Lactose spray - dried      | 20.5    | 18.25   | 16      | 20.5    | 18.25   | 16      | 20.5    | 18.25   | 16      |
| 4     | Cros - Povidone            | 3       | 5.25    | 7.5     | -       | -       | -       | -       | -       | -       |
| 5     | Cros-carmellose Sodium     | -       | -       | -       | 3       | 5.25    | 7.5     | -       | -       | -       |
| 6     | Sodium Starch Glycolate    | -       | -       | -       | -       | -       | -       | 3       | 5.25    | 7.5     |
| 7     | Magnesium Stearate         | 3       | 3       | 3       | 3       | 3       | 3       | 3       | 3       | 3       |
| 8     | Talc                       | 3       | 3       | 3       | 3       | 3       | 3       | 3       | 3       | 3       |
|       | TOTAL                      | 150     | 150     | 150     | 150     | 150     | 150     | 150     | 150     | 150     |

## RESULTS

Table 3: Characterization of Metoprolol Succinate Dry Powder

| FORMULATION CODE | LOOSE BULK DENSITY (gm/ml) | TAPPED BULK DENSITY (gm/ml) | CARR'S INDEX (%)  | HAUSNER'S RATIO   | ANGLE OF REPOSE ( $^{\circ}$ ) |
|------------------|----------------------------|-----------------------------|-------------------|-------------------|--------------------------------|
| F1               | $0.61 \pm 0.031$           | $0.64 \pm 0.011$            | $6.25 \pm 0.042$  | $1.06 \pm 0.017$  | $26.65 \pm 0.033$              |
| F2               | $0.62 \pm 0.021$           | $0.67 \pm 0.048$            | $10.40 \pm 0.021$ | $1.12 \pm 0.014$  | $30.01 \pm 0.023$              |
| F3               | $0.42 \pm 0.023$           | $0.51 \pm 0.021$            | $15.00 \pm 0.031$ | $1.19 \pm 0.025$  | $28.25 \pm 0.026$              |
| F4               | $0.85 \pm 0.011$           | $1.04 \pm 0.012$            | $15.0 \pm 0.010$  | $1.176 \pm 0.041$ | $25.05 \pm 0.011$              |
| F5               | $0.54 \pm 0.042$           | $0.61 \pm 0.011$            | $10.0 \pm 0.032$  | $1.111 \pm 0.012$ | $24.43 \pm 0.024$              |
| F6               | $0.42 \pm 0.021$           | $0.48 \pm 0.021$            | $12.5 \pm 0.041$  | $1.142 \pm 0.011$ | $23.84 \pm 0.022$              |
| F7               | $0.6 \pm 0.043$            | $0.66 \pm 0.041$            | $9.09 \pm 0.011$  | $1.1 \pm 0.048$   | $30.02 \pm 0.014$              |
| F8               | $0.6 \pm 0.041$            | $0.68 \pm 0.062$            | $11.7 \pm 0.012$  | $1.2 \pm 0.054$   | $24.52 \pm 0.016$              |
| F9               | $0.6 \pm 0.022$            | $0.66 \pm 0.042$            | $9.09 \pm 0.010$  | $1.1 \pm 0.015$   | $25.13 \pm 0.021$              |

Table 4: Physico Chemical Evaluation of Metoprolol Succinate Core Tablets

| FORMULATION CODE | THICKNESS (mm) | HARDNESS (Kg/cm <sup>2</sup> ) | FRIABILITY (%) | WEIGHT VARIATION (mg) | WETTING TIME (mg) | WATER ABSORPTION RATIO (mg) | DISINTEGRATION TIME (sec) | DRUG CONTENT (%) |
|------------------|----------------|--------------------------------|----------------|-----------------------|-------------------|-----------------------------|---------------------------|------------------|
| F1               | 2.8 ± 0.02     | 4.13 ± 0.04                    | 0.686 ± 0.06   | 149.75 ± 0.22         | 8.9               | 194.1 ± 0.07                | 21.3                      | 8.7 ± 0.18       |
| F2               | 3.0 ± 0.03     | 4.12 ± 0.06                    | 0.698 ± 0.05   | 151.05 ± 0.25         | 8.8               | 196.5 ± 0.03                | 20.9                      | 99.2 ± 0.10      |
| F3               | 2.9 ± 0.01     | 4.15 ± 0.02                    | 0.629 ± 0.08   | 149.83 ± 0.21         | 9.4               | 198.3 ± 0.05                | 19.5                      | 99.7 ± 0.13      |
| F4               | 2.9 ± 0.02     | 4.18 ± 0.01                    | 0.638 ± 0.04   | 150.28 ± 0.30         | 9.5               | 190.8 ± 0.05                | 25.4                      | 99.4 ± 0.12      |
| F5               | 2.7 ± 0.05     | 4.20 ± 0.03                    | 0.701 ± 0.07   | 148.97 ± 0.31         | 9.3               | 193.3 ± 0.04                | 23.6                      | 98.3 ± 0.14      |
| F6               | 3.1 ± 0.02     | 4.17 ± 0.04                    | 0.674 ± 0.02   | 149.27 ± 0.28         | 8.2               | 182.6 ± 0.02                | 22.3                      | 99.8 ± 0.11      |
| F7               | 2.7 ± 0.04     | 4.19 ± 0.05                    | 0.643 ± 0.03   | 151.13 ± 0.20         | 9.4               | 186.4 ± 0.03                | 26.3                      | 98.8 ± 0.1       |
| F8               | 2.6 ± 0.05     | 4.16 ± 0.07                    | 0.658 ± 0.09   | 149.92 ± 0.24         | 9.1               | 179.2 ± 0.01                | 25.5                      | 98.9 ± 0.16      |
| F9               | 2.8 ± 0.03     | 4.18 ± 0.02                    | 0.697 ± 0.04   | 150.33 ± 0.25         | 8.9               | 184.8 ± 0.07                | 23.8                      | 99.5 ± 0.14      |

Table 5: Dissolution Data of Metoprolol Succinate Core Tablet

| TIME | PERCENTAGE DRUG RELEASE |       |       |       |       |       |       |       |       |
|------|-------------------------|-------|-------|-------|-------|-------|-------|-------|-------|
|      | F1                      | F2    | F3    | F4    | F5    | F6    | F3    | F6    | F9    |
| 0    | 00                      | 00    | 00    | 00    | 00    | 00    | 0     | 0     | 0     |
| 5    | 49.90                   | 75.10 | 93.27 | 60.87 | 79.85 | 91.80 | 93.27 | 91.80 | 93.76 |
| 10   | 74.78                   | 89.67 | 97.03 | 75.60 | 88.69 | 94.74 | 97.03 | 94.74 | 97.85 |
| 15   | 86.23                   | 96.05 | 99.98 | 87.70 | 94.09 | 95.72 | 99.98 | 95.72 | 98.67 |
| 20   | 95.72                   | 99.49 | -     | 93.27 | 95.56 | -     | -     | -     | -     |
| 25   | 99.49                   | -     | -     | 95.07 | -     | -     | -     | -     | -     |

Table 6: Formulation of Metoprolol Succinate Press - Coated Tablets with Optimized Formulation using Polymers

| S. NO. | INGREDIENTS                                      | P1  | P2  | P3  | P4  | P5  | P6  | P7  |
|--------|--|-----|-----|-----|-----|-----|-----|-----|
| 1      | Metoprolol Succinate Core Tablet (Cros-Povidone) | 150 | 150 | 150 | 150 | 150 | 150 | 150 |
| 2      | Xanthum Gum                                      | 300 | -   | 150 | 200 | 100 | 225 | 75  |
| 3      | Guar Gum   | -   | 300 | 150 | 100 | 200 | 75  | 225 |
|        | TOTAL (mg)                                       | 450 | 450 | 450 | 450 | 450 | 450 | 450 |

Table 7: Evaluation of Metoprolol Succinate Pusatile Tablets with Optimized Formulation using Polymers

| FORMULATION CODE | THICKNESS (mm) | HARDNESS (Kg/cm <sup>2</sup> ) | FRIABILITY (%) | WEIGHT VARIATION (mg) | SWELLING INDEX (%) | DRUG CONTENT (%) |
|------------------|----------------|--------------------------------|----------------|-----------------------|--------------------|------------------|
| P1               | 6.79 ± 0.03    | 5.60 ± 0.30                    | 0.718 ± 0.10   | 449.78 ± 0.22         | 21.2 ± 0.09        | 99.34 ± 0.13     |
| P2               | 6.86 ± 0.02    | 5.62 ± 0.25                    | 0.708 ± 0.09   | 450.02 ± 0.15         | 63.9 ± 0.01        | 98.27 ± 0.15     |
| P3               | 6.82 ± 0.04    | 5.51 ± 0.30                    | 0.690 ± 0.06   | 449.67 ± 0.29         | 38.9 ± 0.03        | 99.23 ± 0.12     |
| P4               | 6.85 ± 0.01    | 5.53 ± 0.23                    | 0.701 ± 0.05   | 449.77 ± 0.25         | 33.4 ± 0.17        | 97.85 ± 0.17     |
| P5               | 6.80 ± 0.05    | 5.57 ± 0.27                    | 0.702 ± 0.07   | 451.07 ± 0.18         | 45.5 ± 0.10        | 98.66 ± 0.12     |
| P6               | 6.76 ± 0.03    | 5.55 ± 0.26                    | 0.697 ± 0.03   | 450.01 ± 0.13         | 28.3 ± 0.12        | 98.56 ± 0.11     |
| P7               | 6.87 ± 0.02    | 5.59 ± 0.20                    | 0.701 ± 0.08   | 449.32 ± 0.28         | 53.8 ± 0.06        | 99.23 ± 0.14     |

Table 8: Dissolution Data of Metoprolol Succinate Pulsatile Tablets

| TIME (HOURS) | PERCENTAGE DRUG RELEASE |       |       |       |       |        |       |
|--------------|-------------------------|-------|-------|-------|-------|--------|-------|
|              | P1                      | P2    | P3    | P4    | P5    | P6     | P7    |
| 0            | 00                      | 00    | 00    | 00    | 00    | 00     | 00    |
| 1            | 10.58                   | 8.25  | 5.09  | 3.94  | 2.37  | 6.75   | 2.94  |
| 2            | 21.23                   | 18.07 | 12.47 | 9.49  | 8.67  | 14.39  | 6.36  |
| 3            | 34.85                   | 31.69 | 24.23 | 21.25 | 18.49 | 27.98  | 14.57 |
| 4            | 47.61                   | 44.42 | 37.84 | 35.11 | 31.69 | 41.47G | 27.93 |
| 5            | 60.73                   | 58.28 | 51.18 | 47.82 | 45.38 | 54.26  | 42.46 |
| 6            | 72.52                   | 70.19 | 64.24 | 61.64 | 58.25 | 67.12  | 55.71 |
| 7            | 83.48                   | 81.77 | 76.51 | 74.33 | 71.21 | 79.11  | 68.32 |
| 8            | 95.75                   | 94.63 | 89.18 | 87.21 | 83.06 | 91.42  | 80.59 |




Figure 2: Dissolution Profiles of Metoprolol Succinate Press-Coated Tablets with Optimized Formulation using Xanthum Gum and Guar Gum




Figure 3: Zero Order Plots of Metoprolol Succinate Pulsatile Tablets




Figure 4: First Order Plots of Metoprolol Succinate Pulsatile Tablets




Figure 5: Higuchi Plots of Metoprolol Succinate Pulsatile Tablets




Figure 6: Peppas Plots of Metoprolol Succinate Pulsatile Tablets

Table 9: Comparison of Dissolution Kinetics

| Formulations | Correlation Coefficient |             |         |        | K Value (mg/min.) | T <sub>50</sub> (hr) | T <sub>90</sub> (hr) | n Value |
|--------------|-------------------------|-------------|---------|--------|-------------------|----------------------|----------------------|---------|
|              | Zero Order              | First Order | Higuchi | Peppas |                   |                      |                      |         |
| P1           | 0.9987                  | 0.8394      | 0.8563  | 0.9990 | 11.947            | 4.18                 | 7.53                 | 1.022   |
| P2           | 0.9938                  | 0.8449      | 0.8277  | 0.9985 | 11.564            | 4.32                 | 7.78                 | 0.918   |
| P3           | 0.9745                  | 0.8784      | 0.7732  | 0.9977 | 10.512            | 4.75                 | 8.56                 | 0.703   |
| P4           | 0.9599                  | 0.8777      | 0.7443  | 0.9949 | 10.069            | 4.96                 | 8.93                 | 0.577   |
| P5           | 0.9501                  | 0.8934      | 0.7271  | 0.9953 | 9.516             | 5.25                 | 9.45                 | 0.413   |
| P6           | 0.9853                  | 0.8743      | 0.8003  | 0.9964 | 11.002            | 4.54                 | 8.18                 | 0.817   |
| P7           | 0.9300                  | 0.8864      | 0.6966  | 0.9884 | 9.022             | 5.54                 | 9.97                 | 0.400   |

### Compatibility Studies:

Table 10: IR Interpretation data

|         |                    |
|---------|--------------------|
| 3867.95 | O-H (Stretching)   |
| 3620.64 | N-H (Stretching)   |
| 1552.65 | Aromatic rings     |
| 1374.58 | -O-C (Stretching)  |
| 1234.41 | C-O-C (Stretching) |
| 583.86  | C-H (Bending)      |






Figure 7



**Figure 8**  
: FT-IR of Metoprolol Succinate + Cros-Carmellose-Sodium



**Figure 9**




Figure 10




Figure 11




Figure 12

Figure 7-12: IR Spectrums of Metoprolol succinate and Metoprolol succinate mixtures

Table 11: Stability Studies of Optimized Formulation (P7) at Room Temp. (30<sup>0</sup>C – 40<sup>0</sup>C)

| PARAMETER                   | BEFORE STABILITY STUDIES | AFTER STABILITY STUDIES |
|-----------------------------|--------------------------|-------------------------|
| Appearance                  | Off-White                | Off-White               |
| Drug Content (%)            | 99.23 ± 0.14             | 99.10 ± 0.08            |
| Drug Release after 8hrs (%) | 80.59 ± 0.13             | 80.09 ± 0.07            |




Figure 13: In-Vitro Drug Release Profile of Optimized Formulation (P7) Before and After Stability Studies

---

## DISCUSSION

### Pre-compression parameters:

The powder blends of all the formulation were assessed for physical parameters like Angle of Repose, Loose Bulk Density, Tapped Bulk Density, Compressibility Index and Hausner's Ratio. The outcomes are accounted for in **Table 3**.

From the above examinations, the consequence of Angle of Repose ( $\leq 30$ ) showed great flow properties of the powder. This was additionally bolstered by Compressibility Index ( $\leq 15$ ) likewise Hausner's ratio ( $< 1.25$ ). Every one of these outcomes demonstrated that the powder blend has free flowing nature.

### Post-compression boundaries:

The consequences of physicochemical assessment of tablets for all the formulations are appeared in **Table 4**. From the above outcomes, all the formulations demonstrated uniform thickness, hardness of the tablets was acceptable and the percent friability for all the formulations were underneath 1% showing that friability was inside as far as possible. Good and uniform drug content ( $> 98\%$ ) was seen inside the clumps of various tablet formulations.

Water absorption ratio and wetting time are significant rules for understanding the limit of disintergrants to expand in nearness of

little measure of water, because of its quick water engrossing nature.

Disintegration time is significant for time-release tablets which are wanted to be under 60 seconds for orally breaking down tablets. This quick breaking down helps gulping and furthermore assumes a job in drug absorption in buccal cavity, subsequently advancing bioavailability. Disintegration time of prepared core tablets is in the scope of 19.5 to 26.3 seconds and the order is seen as:

Sodium Starch Glycolate < Cros-Carmellose Sodium < Cros-Povidone

This finding is in concurrence with results acquired from wetting time, since Cros-Povidone swells with more gelling than Cros-Carmellose Sodium and Sodium Starch Glycolate, which broaden disintegration time results that increasing concentration of super disintergrants in the formulation diminishes the breaking down time.

The in vitro dispersion time of the Formulation F3 (figured with Cros-Povidone) was viewed as better than Cros-Carmellose Sodium and Sodium Starch Glycolate considering the wetting time, Disintegration time, % Friability and % Drug release. The Formulation F3 was considered as the fast dissolving tablet formulation among the entirety of the formulations arranged and tried in this investigation and

was then utilized further for getting ready time-release tablets by press-coating technique.

#### **Drug-Excipient Compatibility:**

IR Spectra of the medication and different excipients are appeared in **Figure 7-12** uncovered that there was no incompatibility among drug and excipients on account of no adjustment in the wave numbers of functional groups of metoprolol succinate as appeared in table 10.

#### **Studies on Metoprolol Succinate Pulsatile Tablets utilizing Optimized Formulation Press-Coated with Xanthum Gum and Guar Gum:**

The consequences of physicochemical assessment of tablets for the formulations P1, P2, P3, P4, P5, P6 and P7 are appeared in **Table 7**.

To consider the impact of Xanthum gum and Guar gum on discharge rate of Metoprolol Succinate from the tablets, various concentrations of Xanthum gum and Guar gum were utilized alone (Formulations P1, P2) and in mixes (Formulations P3, P4, P5, P6, P7) for coating of core tablets/optimized formulation. The dissolution information is appeared in **Table 8** and **Figure 2**, Release mechanism and kinetic data appeared in **Table 9**. The drug release followed Zero order kinetics as the graph (**Figure 4**) was

plotted between the Amount of drug release verses time were seen as straight. To learn the mechanism of drug release, the information was exposed to Peppas equation as the chart (**Figure 6**) plotted between the Log % Drug Released verses Log Time was seen as linear.

From the above outcomes it was discovered that among all the formulations, the press-coated tablet formulated with 75 and 225 mg of Xanthum gum and Guar gum respectively i.e Formulation P7 showed just 14.57% of medication discharge up to 3 hrs also, 80.59% of medication discharge at 8 hrs demonstrating to be a decent arrangement with pulsatile drug delivery because of more lag time and in this way by continuing the medication discharge for longer time stretch. Negligible measure of medication discharge during introductory long stretches of lag time should be because of loose matrix on barrier layer at the time of swelling, perhaps purpose behind the minor sum spillage of the medication. The capacity of the pre-owned gums in various extents to support the discharge follows the request:

P7> P5> P4> P3> P6> P2> P1

#### **Stability Studies:**

Stability studies of the optimized formulation of press-coated tablets of Metoprolol Succinate were completed to decide the

impact of added substances in formulation on the stability of the medications and furthermore to decide the physical dependability of the formulation with the progression of time as per the ICH rules. The outcomes appeared in **Table 11** shows that the drug release pattern after stability study is almost the equivalent with no huge contrast. Likewise, the formulation indicated the qualities of stable measurements structure with no adjustment in the physicochemical properties. Thus, it tends to be reasoned that the optimized formulation has great security on the necessary stockpiling condition during its timeframe of realistic usability.

#### **SUMMARY AND CONCLUSION**

The circadian issue by and large require Chronopharmacotherapy, which can be effectively consummate by pulsatile drug delivery system in a sorted out way. With the appearance of pulsatile drug delivery, one can remain ensured for accomplishment of sheltered and powerful treatment. Albeit a few achievements have been accomplished in this regard, there are still some unfamiliar features of pulsatile drug delivery that can open new vistas through better building of the equivalent. The market for drug delivery systems has made considerable progress and will keep on developing at a noteworthy rate.

The exploration work was expected to figure pulsatile release tablets of metoprolol succinate for chronopharmacotherapy of hypertension. Pulsatile release tablets with swellable core and semipermeable layer of polymer were manufactured by utilizing direct compression technique. Super disintegrants like Croscoll, Croscoll-Carmellose Sodium and Sodium Starch Glycolate were utilized for the formulation of core tablets. Xanthan gum and Guar gum were the polymers utilized for coating and to give adequate lag time to timed release of metoprolol succinate. At the point when the formulated tablets interact with dissolution media, water infiltrates into the tablet through the external coating and the core swells because of essence of expanding specialist which makes pressure inside the coated tablet, bringing about the medication discharge by diffusion process. The aftereffects of in-vitro dissolution tests demonstrate that measure of polymer in the formulation influences the medication discharge rate. These outcomes likewise show that the in-vitro lag time before medicate discharge could be utilized to foresee the in-vivo lag time of medication discharge. Along these lines, press coated time – release formulations that control the plasma drug concentrations by design show

guarantee as timed release drug delivery systems.

#### ACKNOWLEDGMENTS

The author is thankful to the Management, Karpagam Academy of Higher Education, Coimbatore, Tamilnadu for providing all the necessary facilities to carry out this research work.

#### REFERENCES

- [1] Haribansh Narayan Singh, Shivangi Saxena, Sunil Singh, Ajit Kumar Yadav. Pulsatile Drug Delivery System: Drugs Used In the Pulsatile Formulations. *Research Journal of Pharmaceutical Dosage Forms and Technology*, 2013, Vol. 5(3): 115-121.
- [2] Rajan K. Verma and Sanjay Garg. Current Status of Drug Delivery Technologies and Future Directions. *Pharmaceutical Technology On-Line*, 2001, Vol. 25 (2): 1–14.
- [3] Shyamala Bhasakaran, Sofiya Moris and Akhtar Sheikh. Design and Development of Chronomodulated System for Arthritis. *International Journal of Pharmaceutical and Chemical Sciences*, ISSN: 2277 – 5005, 2012, Vol. 1 (4): 1350-1361.
- [4] Bhargavi. T. Chronopharmacokinetics. *Tropical Journal of Pharmaceutical Research*, 2009, Vol. 8 (5): 467 – 475.
- [5] Kumar Amit and Ranga Sonam. Pulsatile Drug Delivery System: Method and Technology Review. *International Journal of Drug Development and Research*, ISSN: 0975-9344, 2012, Vol. 4(4): 95-107.
- [6] Supriya. Shidhaye, Ashwini. Dhone, Tejal. Budhkar and Chaitali. Surve. Technologies in Pulsatile Drug Delivery System. *International Journal of Advances in Pharmacy, Biology and Chemistry*, ISSN: 2277-4688, 2012, Vol. 1(4): 438-445.
- [7] Shyamala Bhasakaran, Sofiya Moris and Akhtar Sheikh. Design and Development of Chronomodulated System for Arthritis. *International Journal of Pharmaceutical and Chemical Sciences*, ISSN: 2277–5005, 2012, Vol. 1 (4): 1350-1361.
- [8] Lemmer B. Cardiovascular Chronobiology and Chronopharmacology. *Biologic Rhythms in Clinical and Laboratory Medicine* 1992; 418–427.
- [9] Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN *et al.* Concurrent morning

- increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. *N Engl J Med* 1987; 316(24): 1514–1518.
- [10] Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. *Circulation* 1989; 79(4): 733–743.
- [11] Gambhire Kedar, Mansuk Avinash, Lakkad Harish. Recent Technologies in Pulsatile Drug Delivery System. *International Journal of Pharmacy*, ISSN: 2249–7692, 2014, Vol. 4(2): 76-84.
- [12] Drayer JJ, Weber MA, Nakamura DK. Automated ambulatory blood pressure monitoring: a study in age-matched normotensive and hypertensive men. *Am Heart, J* 1985; 109(6): 1334–1338.
- [13] Suresh V. Gami, Mukesh C. Gohel, Rajesh K. Parikh, Laxman D. Patel, Vipul P. Patel. Design And Evaluation Study Of Pulsatile Release Tablets of Metoprolol Succinate. *An International Journal of Pharmaceutical Sciences*, ISSN: 0976-7908, 2012 Vol. 3(2): 171-181.
- [14] Sravanthi B, Dr. Hindustan Abdul Ahad, Sreeramulu J, Naresh Babu G. Effect Of Polymers In Release Rate Of Metoprolol Succinate In Pulsatile Release Tablets. *International Journal of Chemistry and Pharmaceutical Sciences*, ISSN: 2321-3132, 2013, Vol.1 (3): 224-231
- [15] Sathyaraj And K. Abhinav Formulation And Evaluation Of Metoprolol Succinate Controlled Release Tablets Using Natural And Synthetic Polymer. *International Journal of Pharmaceutical Sciences and Research*, ISSN: 0975-8232, 2012, Vol. 3(1): 247-256.
- [16] Krishnaveni.G, Muthukumar.M, Krishnamoorthy.B. Development And Evaluation Of Pulsatile Drug Delivery System Containing Montelukast Sodium By Press Coated Tablet Using Natural Polysaccharides. *International Journal of Advanced Pharmaceutical Genuine Research*, ISSN: 2347-5102, 2013, Vol. 1(2): 41-51.
- [17] Rajashree S. Masareddy, Gupta Alok Nath L, Danish Kurien. Development and Characterization of Diltiazem Hydrochloride

- Pulsatile Drug Delivery System for Chronomodulated Therapy. Asian Journal of Pharmaceutical and Clinical Research, ISSN: 0974-2441, 2011, Vol. 4(2): 168-173.
- [18] Kamat Akshay Ramesh, Shabaraya A. R., Azharuddin Mohd., Krishnananda Kamath. Formulation and Evaluation of Pulsatile Drug Delivery System Containing Indomethacin Using Natural Polymers. International Research Journal of Pharmacy, ISSN: 2230 – 8407, 2013, Vol. 4(2):111-114.
- [19] Janugade B. U., Patil S. S., Patil S. V., Lade P. D. Formulation And Evaluation Of Press-Coated Montelukast Sodium Tablets For Pulsatile Drug Delivery System. International Journal of Chemtech Research Coden (USA), ISSN: 0974-4290, 2009, Vol.1 (3): 690-691.
- [20] Pallavi M. Chaudhari and Pravin D. Chaudhari. Formulation and Evaluation of Multiparticulate System for Chronotherapeutic Delivery of Salbutamol Sulphate. Journal of Pharmacy and Bioallied Sciences, 2012, Vol. 4(1): 71–73.
- [21] V. Kamalakkannan, C. Kannan, K. Jaganathan, K. S. G. Arul Kumaran and R. Sambath Kumar. Formulation And In-Vitro Evaluation Of Aceclofenac Pulsatile Tablets As An Oral - Time Controlled Drug Delivery System. Archives of Applied Science Research, 2013, Vol. 5 (2): 121-131.